Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,896,803
  • Shares Outstanding, K 17,563
  • Annual Sales, $ 251,450 K
  • Annual Income, $ 143,320 K
  • 60-Month Beta 1.27
  • Price/Sales 7.33
  • Price/Cash Flow 11.19
  • Price/Book 2.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.42
  • Number of Estimates 1
  • High Estimate 0.42
  • Low Estimate 0.42
  • Prior Year 1.43
  • Growth Rate Est. (year over year) -70.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.50 +3.21%
on 11/20/19
114.49 -7.60%
on 11/27/19
-3.01 (-2.77%)
since 11/08/19
3-Month
84.45 +25.27%
on 09/10/19
114.49 -7.60%
on 11/27/19
+19.54 (+22.66%)
since 09/09/19
52-Week
84.45 +25.27%
on 09/10/19
154.25 -31.42%
on 12/11/18
-39.82 (-27.35%)
since 12/07/18

Most Recent Stories

More News
Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 105.79 (-2.05%)
Ligand Enters into Worldwide OmniAb(R) Platform License Agreement with Sanofi

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand's full OmniAb antibody...

LGND : 105.79 (-2.05%)
Ligand Pharmaceuticals Ranked in Deloitte's 2019 Technology Fast 500(TM)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it ranked in Deloitte's Technology Fast 500(TM), a listing of the 500 fastest-growing technology, media, telecommunications, life sciences...

LGND : 105.79 (-2.05%)
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C....

LGND : 105.79 (-2.05%)
Ligand to Participate in the Stephens 2019 Nashville Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat...

LGND : 105.79 (-2.05%)
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

NVS : 92.53 (+0.50%)
AMGN : 232.82 (-0.41%)
LGND : 105.79 (-2.05%)
CASI : 3.19 (-0.62%)
Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates

Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LGND : 105.79 (-2.05%)
Ligand: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Tuesday reported a third-quarter loss of $15.3 million, after reporting a profit in the same period a year earlier.

LGND : 105.79 (-2.05%)
Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned...

IPA.VN : 0.530 (-8.62%)
IPATF : 0.4184 (-2.01%)
LGND : 105.79 (-2.05%)
Ligand Reports Third Quarter 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2019 and provided an operating forecast and program updates. Ligand...

LGND : 105.79 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 110.42
1st Resistance Point 108.10
Last Price 105.79
1st Support Level 104.57
2nd Support Level 103.35

See More

52-Week High 154.25
Fibonacci 61.8% 127.59
Fibonacci 50% 119.35
Fibonacci 38.2% 111.11
Last Price 105.79
52-Week Low 84.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar